Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN

NCT03878979 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer
Head and Neck Cancer Metastatic

Interventions

DRUG: Nivolumab 480mg and surgical resection

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]